Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-47

I had taken some loose notes from the call as I tried to follow the conversation pretty closely (I will need to listen to recording for clarification on few things). I was happy with where this treatment could go based on initial analysis of the sub group of 20. That sub group had maximal Eylea treatment prior to the study. They had on average 9 months treatment of Eylea (9 x 4 weekly injections) yet it was this maximally pre-treated group which had the best results with opt-302. This was the surprise to clinicians. Of course, this sub-group was low in statistical power but the trend seemed evident to clinicians and further treatment beyond the 3 months would have amplified this trend, according to them.